Banner

COMBINED INTRACAVERNOUS VASOACTIVE DRUGS AND PHOSPHODIESTERASE– 5 INHIBITORS IN THE MANAGEMENT OF SEVERE ERECTILE DYSFUNCTION

• 2011
Back
Publication Information
Authors Ahmed Mahmoud Al-Adl; Osama Abdel-Wahab; Tarek El-Karamany; Ashraf Abdel Aal
Keywords Not Available
Journal Not Available
Publisher Not Available
Volume Not Available
Issue Not Available
Pages Not Available
publication.type International
Paper Link Not Available
Supplementary Materials Not Available
Abstract
PURPOSE: To evaluate the clinical response and hemodynamic changes in the cavernosal arteries to combined therapy with trimix injection and sildenafil citrate in men with severe erectile dysfunction.
PATIENTS AND METHODS: In all 40 patients were evaluated. Mean age 50.7 + 11.3 years. Fifteen patients (37.5%) with moderate ED and 25 (62.5%) with severe ED. Patients received 25 mg sildenafil once daily for 8 weeks and ICI with 0.25 mL trimix twice weekly. The penile hemodynamics were evaluated with Color Doppler ultrasound (CDUS) done at the begging and repeated after 8 weeks. Erection Hardness Score and satisfaction with treatment (EDITS) were assessed.
RESULTS: Pretreatment hemodynamic parameters revealed normal response in five (12.5%), arterial insufficiency in five (12.5%), Veno-occlusive dysfunction in 26 (65%) and mixed arterial and VOD in 4 cases (10%). Improvement was found in 28 patients (70%); their mean age was 46.1 + 8.9 and range from 35 to 65 years. Adverse effects reported in 17 patients (42.5%).
Responders revealed significant improvement in hemodynamic parameters, SHIM-5 score, time to and duration of erection and EHS. Comparison between responders and non-responders revealed significant difference regarding age, duration of ED, pre and post-treatment SHIM-5 score, time to and duration of erection, EHS with therapy and mean and standardized EDITS.
CONCLUSION: The combination of ICI with triple agents plus oral PDE-5 inhibitor is an effective therapy in the patients with severe ED who do not respond to PDE-5 inhibitors or ICI of PGE1 monotherapy.
Key